DOTA-JR11

• UNSPSC Description:

  DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research[1].

• Target Antigen:

  Radionuclide-Drug Conjugates (RDCs); Somatostatin Receptor

• Type:

  Peptides

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dota-jr11.html

• Purity:

  98.81

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](C(N[C@H](C(N[C@@](C(N[C@@H](CSSC[C@H](C(N1)=O)NC([C@@H](NC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC3=CC=C(C=C3)Cl)=O)C(N[C@@H](C(N)=O)CC4=CC=C(C=C4)O)=O)=O)([H])[C@H](O)C)=O)CCCCN)=O)CC5=CC=C(C=C5)NC(N)=O)[C@@H]1CC6=CC=C(C=C6)NC([C@@H]7CC(NC(N7)=O)=O)=O

• Molecular Weight:

  1689.27

• References & Citations:

  [1]Krebs S, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057.|[2]Xie Q, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3129-3140.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported

• CAS Number:

  1039726-31-2